As Shareholder Vote Looms, Genesis Provides New Details on ssRNAi Subsidiary | GenomeWeb

By Doug Macron

New Zealand's Genesis Research and Development this month provided additional details about the establishment of a subsidiary to develop and commercialize its single-stranded RNAi technology, revealing that the primary investor in the new company is Japanese biotech firm MediBic Group.

And while MediBic is primarily a pharmacogenomics company, it is not entirely a stranger to RNAi, having invested at least twice in Intradigm through its investment banking arm MediBic Alliance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.